<DOC>
	<DOCNO>NCT01287741</DOCNO>
	<brief_summary>This open-label , randomize , parallel group study evaluate efficacy safety obinutuzumab combination cyclophosphamide , doxorubicin , vincristine , prednisolone prednisone ( CHOP ) chemotherapy versus rituximab ( MabThera/Rituxan ) CHOP previously untreated participant cluster differentiation 20 ( CD20 ) -positive diffuse large B-cell lymphoma ( DLBCL ) . Participants randomize receive either obinutuzumab 1000 milligram ( mg ) intravenously ( IV ) every 21 day rituximab 375 milligram per square meter ( mg/m^2 ) IV every 21 day 8 cycle , addition 6-8 cycle CHOP chemotherapy IV every 21 day . Participants randomize obinutuzumab arm receive additional two dos Days 8 15 Cycle 1 . Anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study Obinutuzumab Combination With CHOP Chemotherapy Versus Rituximab With CHOP Participants With CD20-Positive Diffuse Large B-Cell Lymphoma ( GOYA )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Previously untreated CD20positive DLBCL At least 1 bidimensionally measurable lesion ( great [ &gt; ] 1.5 centimeter [ cm ] large dimension compute tomography [ CT ] scan ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Adequate hematological function Lowintermediate , intermediate highrisk International Prognostic Index ( IPI ) score ( lowrisk IPI score : IPI 1 irrespective bulky disease IPI 0 bulky disease , define one lesion great equal ( &gt; /= ) 7.5 cm ) Left ventricular ejection fraction ( LVEF ) &gt; /=50 percent ( % ) cardiac multiplegated acquisition ( MUGA ) scan cardiac echocardiogram History severe allergic anaphylactic reaction humanize murine monoclonal antibody know sensitivity allergy murine product component CHOP obinutuzumab Contraindication individual component CHOP , include prior receipt anthracyclines Participants transform lymphoma patient follicular lymphoma IIIB Prior therapy DLBCL , exception nodal biopsy local irradiation Prior treatment cytotoxic drug rituximab another condition ( example , rheumatoid arthritis ) prior use antiCD20 antibody Prior use monoclonal antibody within 3 month start Cycle 1 Corticosteroid use &gt; 30 milligram per day ( mg/day ) prednisone equivalent , purpose lymphoma symptom control Primary central nervous system ( CNS ) lymphoma secondary CNS involvement lymphoma , mantlecell lymphoma ( MCL ) , histologic evidence transformation Burkitt lymphoma , primary mediastinal DLBCL , primary effusion lymphoma , plasmablastic lymphoma , primary cutaneous DLBCL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>